Articles On Medlab Clinical (ASX:MDC)

In order to boost their returns, investors usually tend to search for stocks of the companies that are likely to report relatively higher revenues and earnings in the future. The stocks that are expected to grow substantially above the aver...

Government bodies across the globe are legalising the manufacturing and consumption of medical cannabis products, resulting in vast opportunities for investors. In 2018, Canada became the second largest country in the world to legalise cann...

2018 witnessed several catalysts for the legal cannabis industry, with countries legalising medicinal cannabis, public and private sector getting into constructive discussions about the calibre and cons of the pot industry from a business p...

First revenues from the commercial agreements are expected in early 2020.

The company’s first NanoCBD sale offers validation of the product and differentiated delivery technology and points to the global prospects for Medlab developed products.

It is not often that headlines on the ASX really stand out. Aside from the obvious mining hits, tech partnerships and biotech results, most of the announcements released via the ASX’s platform each day read “daily share buyback notice”, “ap...

Medlab Clinical (ASX: MDC)  is a medical life science company developing therapeutic pathways for diagnosed chronic diseases. The company is focused on the development of therapies for pain management, depression and obesity, as well as ear...

The increasing use of medical cannabis products has prompted many countries to soften the regulations regarding the manufacturing and consumption of cannabis products. Last year, Canada became the second and the largest country in the world...

The clinical study was a blinded, randomised trial showing plasma concentrations were achieved quickly with a product half-life of about four hours.

Australia has established its strong position in the contemporary world that is welcoming the good side of cannabis with open arms, amid the recreational legalising debates. The country joined the bandwagon of Alaska, Canada, North Korea an...

Legalisation of Cannabis in Australia Cannabis is widely used for the remedies of Palliative care, Chronic non-cancer pain, Nausea and vomiting, Multiple sclerosis and many more chronic diseases. Before 2016, the production of cannabis was...

The Medlab Clinical Ltd (ASX: MDC) share price rose 7.7% to a 52-week high of $0.56 in early Monday trade, although it has since dropped back slightly to $0.51 per share at the time of writing. The strong start to the trading week occurred...

Both companies are now working on both the definitive agreement and product market launch.

In 2016, Australia legalised cannabis for medicinal and scientific purposes under the Narcotic Drugs Amendment Act 2016. The amendment provided relief to the cannabis sector and enabled the prospective producers to apply for the necessary l...

Californian cannabis company Caliva has signed on billionaire rapper Shawn “Jay-Z” Carter to promote its brand as the drug becomes legal recreationally in more states. Caliva said Jay-Z, as the company’s chief brand strategist, would “play...

Wth the legalisation of medical cannabis in many countries like Canada, the global medical cannabis industry has boomed quite a bit in recent times. Let’s take a quick look at 20 cannabis companies trading on ASX. Cann Group Limited (ASX:...

At the start of the year James Chisholm’s stake in Atrum Coal (ASX:ATU) was just under $4m. But he’s retired from the board and sold his shares to Regal Funds Management, which now holds 13.5 per cent of the company. With Atrum’s rise from...

Do you know that market enthusiasts believe that legalising cannabis would generate approximately $8.5 billion in the country’s federal and state tax? Ponder over the massive revenue that this sector would add to the necessities related to...

Medlab Clincial Ltd (ASX MDC) released an operations update today. The MDC share price jumped 8.57% higher to $0.380 off the back of the news. The company’s revenue during the June 2019 quarter leaped to over $3 million, up about 135% on th...

The Medlab Clinical Ltd (ASX: MDC) share price is up 7.1% to $0.38 in Thursday trade following the release of an operations update this morning. The company announced that it had delivered a very strong June quarter, with progress being ma...

Medlab is a medical research company with a track record of bringing its nutraceutical and cannabis products to market.

An Australian medicinal cannabis company achieved 50 per cent year-on-year revenue growth in the June quarter, backed by a roll-out of its nutraceutical range Priceline and TerryWhite Chemmart pharmacies. Medlab Clinical (ASX: MDC) record...

Like Really? Boxing legend Mike Tyson is developing his own marijuana holiday resort, the Tyson Ranch near Desert Hot Spring. The resort will include a music festival venue, a luxury hotel, the world’s longest lazy river, Tyson University a...

Australian medical life sciences company, Medlab Clinical (ASX:MDC), has received human ethics approval for the second trial of its patented, cannabis-based medicine, NanaBis.

The global stock markets are sensitive to the macro-economic factors and to the news which is critical to the global growth. A rise in the global economic uncertainties and geopolitical tensions have the potential to impact the sentiments o...

Medlab Clinical Ltd Medlab Clinical Limited (ASX: MDC) is primarily engaged in sale of nutraceutical products (a mix of nutrition and pharmaceutical food product). It is also involved in pharmaceutical research and commercialisation. On 18...

Medlab expects to roll this trial out to 2,000 patients across Australia, making it one of the most significant cannabis trials to date.

Medical science company Medlab Clinical (ASX: MDC) is steadily ticking boxes as it seeks regulatory clearance for its medicinal mouth spray product. The company announced this morning that it has ethics approval to run observational trial f...

Honey containing THC *might* be able to be exported and imported. The UK is the Next Big Thing in pot, Brexit or no. And 2020 is starting to look like a very hard deadline for a series of big events. There are 30 companies doing, or saying...

Up until about four years ago obesity was an ‘it’ investment trend, as global funds spruiked the ‘sugar is the new tobacco’ theme and companies tested treatments specifically targeted at weight loss. Since then the world has not become any...